Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Single-use percutaneous catheters for intraperitoneal P32 therapy

H O Smith1, D E Gaudette, G L Goldberg

  • 1Department of Obstetrics and Gynecology, Albert Einstein College of Medicine, Bronx, NY 10461.

Cancer
|May 15, 1994
PubMed
Summary

Percutaneous catheter placement for intraperitoneal radioactive chromic phosphate (P32) therapy in ovarian and endometrial cancers is successful in most patients. This method offers a well-tolerated, effective approach without requiring additional surgery.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cervical adenocarcinoma presenting as an ovarian torsion.

Gynecologic oncology reports·2024
Same author

Racial disparities in the treatment of endometrial intraepithelial neoplasia in postmenopausal women.

Gynecologic oncology reports·2024
Same author

Use of aromatase inhibitors in menopausal deep endometriosis: a case report and literature review.

Climacteric : the journal of the International Menopause Society·2021
Same author

The association of sexual dysfunction with race in women with gynecologic malignancies.

Gynecologic oncology reports·2019
Same author

Long-term outcome of postmenopausal women with non-atypical endometrial hyperplasia on endometrial sampling.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2019
Same author

Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial.

Journal of the National Cancer Institute·2015

Area of Science:

  • Oncology
  • Medical Imaging
  • Surgical Procedures

Background:

  • Intraperitoneal (IP) radioactive chromic phosphate (P32) is an investigational treatment for ovarian and endometrial cancers.
  • Percutaneously placed catheters offer a less invasive method for delivering IP P32 therapy, avoiding further surgical intervention.

Purpose of the Study:

  • To evaluate the efficacy and safety of bedside percutaneous catheter placement for IP P32 administration.
  • To determine the technical success rate and complication incidence associated with this procedure.

Main Methods:

  • Twenty-five patients with ovarian and/or endometrial cancer underwent bedside percutaneous catheter placement using a specialized central venous catheter under local anesthesia.
  • No ultrasonographic or radiologic guidance was used during catheter insertion.

Related Experiment Videos

  • Catheter placement occurred a median of 39 days post-laparotomy.

    • Main Results:

    • Successful catheter insertion was achieved in 88% of patients (22/25), with good IP distribution.
    • The technical failure rate was 12%.
    • Bowel entry occurred in 16% of patients but without clinical sequelae; increased attempts correlated with higher complication and bowel entry rates.

    Conclusions:

    • Percutaneous catheter placement for IP P32 therapy is a successful and well-tolerated procedure in the majority of patients.
    • This technique should be considered for patients undergoing IP P32 treatment for gynecologic malignancies.